Axi-cel as Frontline Therapy for High-Risk Large B-cell Lymphoma Produces Encouraging Responses
In 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.
CAR T-Cell Therapy gets Orphan Drug Designation for Acute Lymphoblastic Leukemia
The cell therapy is approved for B-cell non-Hodgkin lymphoma and B-ALL in China.
New Treatment Post-Tisagenlecleucel Being Developed for Patients With LBC Lymphoma
Two sites in California and Missouri are actively recruiting patients with r/r LBCL who were treated with tisagenlecleucel to receive efineptakin alfa in the study.
CD19+ B-Cell Malignancy Cell Therapy Receives RMAT Designation
In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.
The Roles of Stem Cell Transplant and CAR T-Cell Therapy in B-Cell Lymphoma
Doctors debated the roles of allogeneic hematopoietic stem cell transplant and CAR T-cell therapy for the treatment of aggressive B-cell lymphoma.
Mantle Cell Lymphoma Treatment Landscape 1 Year After CAR T Approval
Michael Wang, MD, discussed the evolution of treatment in the MCL space specifically with the emergence of chimeric antigen receptor T cells.
MD Anderson to Offer Solutions to Cell Therapy AEs
The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.
Expert Highlights Contributing Elements to Hemopoietic Recovery From CAR T-Cell Therapy
Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.
Mantle Cell Lymphoma Options Expand, With CAR-T on the Horizon
Kieron Dunleavy, MD, discusses the current treatment paradigm in mantle call lymphoma and the emerging potential for CAR T-cell therapy.